Loading company…
Sichuan Clover develops protein-based vaccines and biologic therapies, including a COVID-19 candidate, from Chengdu, China.
Based in Chengdu, China and founded in 2007, Sichuan Clover Biopharmaceuticals, Inc. is a subsidiary of Clover Biopharmaceuticals, Ltd. developing vaccines and biologic therapies. Its SCB-2019 COVID-19 vaccine candidate was developed with CEPI and Dynavax, and its pipeline also includes Trimer-Tag vaccine and oncology candidates. In 2021 the company raised USD 230 million in Series C funding co-led by GL Ventures and Temasek Holdings, bringing total funding to USD 315 million since 2011.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in